Faculty Profiles - IWASAKI Yoshiaki

MISC - IWASAKI Yoshiaki

Division display 281 - 300 of about 510 ／ All the affair displays >>

Sonazoid造影超音波が存在診断に有用であった肝細胞癌の1例

萩原宏明, 小林功幸, 中村進一郎, 安中哲也, 桑木健志, 歳森淳一, 宮武宏和, 庄司凡, 白羽英則, 岩崎良章, 坂口孝作

超音波医学 35 ( 2 ) 262 - 262 2008.3

肝腫瘍診断におけるHybrid contrast imagingを用いたSonazoid造影超音波の有用性

歳森淳一, 小林功幸, 中村進一郎, 萩原宏明, 安中哲也, 桑木健志, 宮武宏和, 庄司凡, 白羽英則, 岩崎良章, 坂口孝作

超音波医学 35 ( 2 ) 263 - 263 2008.3

C型肝炎-最新治療の進め方-インターフェロン単独治療とその有効性

岩﨑良章, 山本和秀

Medical Practice 25 ( 10 ) 1863 - 1868 2008

特集―C型肝炎のすべて2009 合併症を有する患者のHCV治療―肝硬変に対するIFN治療．

岩﨑良章, 山本和秀

肝胆膵 57 ( 5 ) 975 - 982 2008

Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels

Akiko Fujiwara, Kohsaku Sakaguchi, Shinichi Fujioka, Yoshiaki Iwasaki, Tonionori Senoh, Mamoru Nishimura, Masako Terao, Yasushi Shiratori

JOURNAL OF GASTROENTEROLOGY 43 ( 6 ) 484 - 491 2008

Language：English Publisher：SPRINGER TOKYO

Background. We evaluated the annual rate of fibrosis progression in chronic hepatitis B and C patients with elevated alanine aminotransferase (ALT) levels. Methods. Forty-nine chronic hepatitis B patients and 21 chronic hepatitis C patients, each of whom had undergone two or more liver biopsies at an interval of more than 1 year, were enrolled in this retrospective clinical research protocol. The annual rate of fibrosis progression was calculated by dividing the change in fibrosis stage between the first and second liver biopsies by the interval in years between them. Results. The median interval in chronic hepatitis B and C was 3.4 (first and third quartiles, 1.8-4.7) and 3.2 (2.1-6.5) years, respectively. Overall, the mean fibrosis progression rate was 0.21 +/- 0.31 (mean +/- SD) fibrosis units (FU) per year in 49 patients with chronic hepatitis B, and 0.13 +/- 0.18 FU/year in 21 patients with chronic hepatitis C. The ALT level was an independent variable correlating with fibrosis progression. In patients whose median ALT level was 70 IU/l or more, the mean fibrosis progression rate was 0.28 +/- 0.32 FU/year in 36 patients with chronic hepatitis B, and 0.22 +/- 0.23 FU/year in eight patients with chronic hepatitis C. Conclusion. This paired-biopsy study of untreated chronic hepatitis B or C demonstrated that fibrosis progression occurred largely in patients with continuously elevated ALT levels even over a relatively short period, and that liver fibrosis might progress by one stage within an average of 4-5 years of follow-up in patients with elevated ALT of 70 IU/l or more.

DOI： 10.1007/s00535-008-2183-8

Web of Science

researchmap

Lamivudine treatment improves the prognosis of fulminant hepatitis B

Yasuhiro Miyake, Yoshiaki Iwasaki, Akinobu Takaki, Shin-ichi Fujioka, Kouichi Takaguchi, Hiroshi Ikeda, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori

INTERNAL MEDICINE 47 ( 14 ) 1293 - 1299 2008

Language：English Publisher：JAPAN SOC INTERNAL MEDICINE

Objective The efficacy of lamivudine for fulminant hepatitis B has been reported in Europe and West Asia. However, in these reports, the main infection genotype is D. Furthermore, if lamivudine improves survival, prognostic factors for fulminant hepatitis B may differ from those reported previously. The aim of this study was to clarify the prognostic factors and the efficacy of lamivudine for fulminant hepatitis B in Japan, where the main infection genotype is B.
Methods This study was a retrospective cohort study. We selected 37 consecutive patients with fulminant hepatitis due to acute hepatitis B virus infection. As 4 of them had received liver transplantation, the data of 33 patients with a median age of 45 (range, 20-74) years were analyzed.
Results Lamivudine was administered to 10 patients. There were no differences in clinical features at the time of the diagnosis of fulminant hepatitis B between patients treated with and without lamivudine. Survival rates of patients treated with and without lamivudine were 70% and 26%, respectively. Age (>= 45 years), systemic inflammatory response syndrome, and non-administration of lamivudine were associated with fatal outcomes. The survival rates of patients treated with and without lamivudine, who were in a state of systemic inflammatory response syndrome, were 50% and 9%, and in patients aged >= 45 years, 50% and 8%, respectively.
Conclusion This study suggests the efficacy of lamivudine for fulminant hepatitis B in the area where the main infection genotype is B. We consider that lamivudine is worth administering to patients with fulminant hepatitis B.

DOI： 10.2169/internalmedicine.47.1061

Web of Science

researchmap

Hepatitis C virus could be eradicated with strong immune responses after withdrawing interferon treatment post living donor liver transplantation

Akinobu Takaki, Takahito Yagi, Yoshiaki Iwasaki, Hiroshi Sadamori, Kazuko Koike, Masashi Tatsukawa, Haruhiko Kobashi, Kohsaku Sakaguchi

HEPATOLOGY 46 ( 4 ) 533A - 533A 2007.10

C型肝細胞癌根治後のIFN療法による再発抑制効果に関する検討

萩原宏明, 小林功幸, 岩崎良章, 中村進一郎, 桑木健志, 歳森淳一, 宮武宏和, 三好健司, 坂口孝作, 高口浩一, 大西秀樹, 池田弘, 下村宏之, 岩堂昭太, 能祖一裕, 荒木康之

肝臓 48 ( Suppl.2 ) A443 - A443 2007.9

時間依存性共変量を用いた肝細胞癌患者の予後予測モデルの検討

桑木健志, 小林功幸, 中村進一郎, 岩堂昭太, 萩原宏明, 安中哲也, 歳森淳一, 宮武宏和, 寺田亮, 三好健司, 庄司凡, 高木章乃夫, 岩崎良章, 小橋春彦, 坂口孝作

日本消化器病学会雑誌 104 ( 臨増大会 ) A693 - A693 2007.9

B型劇症肝炎における予後因子の解析

三宅康広, 高木章乃夫, 岩崎良章, 藤岡真一, 高口浩一, 池田弘, 小橋春彦, 坂口孝作

日本消化器病学会雑誌 104 ( 臨増大会 ) A682 - A682 2007.9

腹腔鏡により診断した乳癌肝転移の化学療法に伴うpseudocirrhosisの1例

安中哲也, 小橋春彦, 萩原宏明, 桑木健志, 歳森淳一, 宮武宏和, 庄司凡, 三好健司, 寺田亮, 中村進一郎, 小林功幸, 高木章乃夫, 岩崎良章, 坂口孝作

Gastroenterological Endoscopy 49 ( Suppl.2 ) 2380 - 2380 2007.9

C型慢性肝炎に対するDose escalationによるペグインターフェロン+リバビリン併用療法の有用性

岩崎良章, 荒木康之, 岡本良一, 谷口英明, 牧野泰裕, 大西亨, 下村宏之, 冨田稔, 藪下和久, 石井泰史, 池田弘, 高木章乃夫, 小橋春彦, 坂口孝作, 白鳥康史

肝臓 48 ( Suppl.2 ) A421 - A421 2007.9

非アルコール性脂肪性肝炎(NASH)とアルコール性肝炎の腹腔鏡像及び臨床像の比較検討

庄司凡, 小橋春彦, 安中哲也, 寺田亮, 高木章乃夫, 岩崎良章, 坂口孝作

Gastroenterological Endoscopy 49 ( Suppl.2 ) 2380 - 2380 2007.9

高齢社会の消化器スクリーニングのあり方をめぐって高齢のC型慢性肝炎患者に対する肝癌サーベイランスの意義について(費用効果分析による検討より)

田中弘教, 岩崎良章, Aoki Noriaki

日本消化器病学会雑誌 104 ( 臨増大会 ) A444 - A444 2007.9

特異な経過を辿った劇症B型肝炎の1例

田邊渉, 池田弘, 神野亜希子, 寺島禎彦, 菊池理, 前田有紀, 畑貴子, 山本直樹, 青山育雄, 酒井章裕, 清輔良江, 新井修, 大西秀樹, 金吉俊彦, 下村宏之, 高木章乃夫, 岩崎良章, 坂口孝作

肝臓 48 ( 8 ) 405 - 405 2007.8

脂肪肝と肝機能異常に対する飲酒の影響

守屋昭男, 岩崎良章, 大口創平, 坂口孝作, 白鳥康史

肝臓 48 ( Suppl.1 ) A272 - A272 2007.4

1型高ウイルス量のC型慢性肝炎に対するペグインターフェロン+リバビリン併用療法の解析

岩崎良章, 荒木康之, 高口浩一, 谷口英明, 岡本良一, 川口光彦, 寺田亮, 大澤俊哉, 藤岡真一, 永野拓也, 喜田恵治, 山本和秀, 高木章乃夫, 小橋春彦, 坂口孝作, 白鳥康史

肝臓 48 ( Suppl.1 ) A138 - A138 2007.4

生体肝移植術前管理としての感染コントロールの重要性

高木章乃夫, 八木孝仁, 岩崎良章, 貞森裕, 松川啓義, 松田浩明, 篠浦先, 楳田祐三, 成島道樹, 庄司凡, 寺田亮, 小橋春彦, 田中紀章, 坂口孝作

肝臓 48 ( Suppl.1 ) A237 - A237 2007.4

Limitation of combination therapy of peginterferon and ribavirin for older patients with chronic hepatitis C

Yoshiaki Iwasaki, Yasuyuki Araki, Kouichi Takaguchi, Hideaki Taniguchi, Ryoichi Okamoto, Mitsuhiko Kawaguchi, Ryo Terada, Toshiya Osawa, Shin-Ichi Fujioka, Takuya Nagano, Keiji Kita, Kazuhide Yamamoto, Akinobu Takaki, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori

GASTROENTEROLOGY 132 ( 4 ) A794 - A795 2007.4

Sustained virologic response to previous interferon treatment may reduce the risk for the recurrence of hepatocellular carcinoma in patients with hepatitis C

Hirokazu Miyatake, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Ryo Terada, Kenji Miyoshi, Hideki Ohnishi, Shouta Iwadou, Bon Shoji, Kenji Kuwaki, Junichi Toshimori, Tetsuya Yasunaka, Hiroaki Hagihara, Kohsaku Sakaguchi

GASTROENTEROLOGY 132 ( 4 ) A202 - A202 2007.4

　 PREV - NEXT 　

< IWASAKI Yoshiaki >

MISC - IWASAKI Yoshiaki